{"title":"Dramatic Response to Tezepelumab as an Initial Biologic Agent for Refractory Asthma Associated with Type 2 and Non-type 2 Traits.","authors":"Daisuke Minami, Takeshi Hosoya, Masaharu Hosoya, Akichika Nagano, Yasuhiro Nakajima, Nobuaki Miyahara, Arihiko Kanehiro","doi":"10.18926/AMO/66161","DOIUrl":null,"url":null,"abstract":"<p><p>A 74-year-old Japanese woman presented with a 45-year history of refractory asthma. She had been treated with inhaled corticosteroids, a long-acting β2-agonist, and a long-acting muscarinic antagonist for 6 months. She also had a repeated viral infection. Her condition had been characterized as a refractory asthma associated with type 2 and non-type 2 traits. We began treatment with tezepelumab. The control of the patient's asthma symptoms and quality of life improved greatly within 1 month (changes in eosinophil count from 748 to 96 /μL, in FeNO from 32 to 17 ppb, in the Asthma Quality of Life Questionnaire score from 3.59 to 6.68, and in the Asthma Control Test score from 13 to 23). Tezepelumab was effective as an initial biologic agent for a patient with refractory asthma associated with type 2 and non-type 2 traits.</p>","PeriodicalId":7017,"journal":{"name":"Acta medica Okayama","volume":"77 6","pages":"671-674"},"PeriodicalIF":0.6000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta medica Okayama","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18926/AMO/66161","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
A 74-year-old Japanese woman presented with a 45-year history of refractory asthma. She had been treated with inhaled corticosteroids, a long-acting β2-agonist, and a long-acting muscarinic antagonist for 6 months. She also had a repeated viral infection. Her condition had been characterized as a refractory asthma associated with type 2 and non-type 2 traits. We began treatment with tezepelumab. The control of the patient's asthma symptoms and quality of life improved greatly within 1 month (changes in eosinophil count from 748 to 96 /μL, in FeNO from 32 to 17 ppb, in the Asthma Quality of Life Questionnaire score from 3.59 to 6.68, and in the Asthma Control Test score from 13 to 23). Tezepelumab was effective as an initial biologic agent for a patient with refractory asthma associated with type 2 and non-type 2 traits.
期刊介绍：
Acta Medica Okayama (AMO) publishes papers relating to all areas of basic and clinical medical science. Papers may be submitted by those not affiliated with Okayama University. Only original papers which have not been published or submitted elsewhere and timely review articles should be submitted. Original papers may be Full-length Articles or Short Communications. Case Reports are considered if they describe significant and substantial new findings. Preliminary observations are not accepted.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
